The Technical Analyst
Select Language :
Turning Point [TPTX]

Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology

Turning Point Price, Forecast, Insider, Ratings, Fundamentals & Signals

Turning Point is listed at the NASDAQ Exchange

0.12% $75.49

/ 15 aug 2022 @ 16:00


RATING 2022-09-07
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
1/212/213/214/211/222/22
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -13.55 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
0x
Company: PE -13.55 | industry: PE 0
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 75.30 - 76.73

( +/- 0.94%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-08-17 Nicholson Garry A Sell 23 400 Stock Option (right to buy)
2022-08-17 Nicholson Garry A Sell 8 500 Stock Option (right to buy)
2022-08-17 Nicholson Garry A Sell 8 500 Stock Option (right to buy)
2022-08-17 Machado Patrick Sell 30 000 Stock Option (right to buy)
2022-08-17 George Simeon Sell 8 500 Stock Option (right to buy)
INSIDER POWER
-90.54
Last 94 transactions
Buy: 1 295 935 | Sell: 2 703 326

Forecast: 01:40 - $87.08

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $75.49 (0.12% )
Volume 1.032 mill
Avg. Vol. 0 mill
% of Avg. Vol 0 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Turning Point Therapeutics, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Turning Point Therapeutics, Inc.

RSI

Intraday RSI14 chart for Turning Point Therapeutics, Inc.

Last 10 Buy & Sell Signals For TPTX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Turning Point Therapeutics, Inc.

TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Last 10 Buy Signals

Date Signal @
OSHIUSDMar 29 - 04:4981.91
HBTCUSDMar 29 - 04:3834 558
DESOUSDMar 29 - 04:3931.41
ARUSDMar 29 - 04:28$41.19
KCSUSDMar 29 - 04:24$11.87
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.